Understanding Chronic Viral Infections Better

Crucial infection strategies of chronic viruses have been revealed by understanding the LCMV polymerase that can lead to the development of new antiviral therapeutics.

Understanding the link between chronic viral infections and the molecular interactions of LCMV polymerase can lead to the development of new antiviral therapies, reveals a new study.//

Chronic viral infections like HIV or hepatitis are among the biggest threads to human health worldwide. While an acute viral infection usually results in a full recovery and effective immune memory, chronic viruses evade the immune system and remain permanently in their host´s body.

Basis of Key Immune Protein's Two-Faced Role Unlocked in a Study
A long sought-after partner for a key immune protein, called TIM-3, has been identified by a team from a Brigham and Women's Hospital-led team.

‘Understanding the interaction of cellular proteins with the LCMV polymerase leads to various viral strategies and targets for the development of new antiviral therapeutics.’

Treating such a disease is a difficult task, as the molecular events during the development of a chronic infection remained largely elusive.

With their latest study published in PLOS Pathogens the team of Andreas Bergthaler, Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, in cooperation with the University of Basel and the MRC Laboratory of Molecular Biology Cambridge made an important contribution to the understanding of chronic viral infections:

The scientists established the first comprehensive overview of cellular proteins interacting with the LCMV polymerase, a crucial enzyme for the replication of the virus and for chronic infection. By mapping them in the human proteome, they revealed various viral strategies and potential targets for future antiviral therapeutics.

CD8 T Cells Sometimes Lose Its Ability to Effectively Fight Infections
While fighting chronic viral infections or cancers, a key division of the immune system, known as CD8 T cells, sometimes loses its ability to effectively fight foreign invaders.

In order to perform the study, the researchers with CeMM PhD student Kseniya Khamina as first author - developed a novel approach to tag viral proteins. Therewith, the interactions of the LCMV polymerase with the proteins of the host cells were determined.

Combined with publicly available data from other RNA viruses' polymerase interactomes, the generated dataset allowed a mapping of the cellular pathways targeted by different viral polymerases.

New Insights into Tumor-Infiltrating T Cells may Pave the Way for Precision Medicine
A distinct gene module for T cell dysfunction distinct from activation in tumor-infiltrating T cells has been identified by investigators.

Some of the proteins found to interact with the LCMV polymerase turned out to be essential for the viral life cycle.

"With our newly developed method we were able to show that some proteins, like DDX3X, have a proviral effect they are important binding partners for the virus to survive. Others, like the TRIM21 protein, show more of an antiviral effect, they serve the host cell as an intracellular defense against the pathogen," explains Kseniya Khamina.

Immunity to Dystrophin Revealed in Duchenne Muscular Dystrophy
Duchenne muscular dystrophy has revealed a challenge to researchers as an immune reaction to the defective muscle protein, dystrophin, makes it difficult to strenghten patients' muscles.

"Mice lacking the TRIM21 protein entirely showed an impaired virus control when infected with a chronic strain of LCMV."

"The results of our study provide the first comprehensive overview of the molecular binding partners of the LCMV polymerase. Furthermore, their mapping in the human proteome reveals important infection strategies of chronic viruses," Andreas Bergthaler summarizes the findings.

"We hope that our research leads to a better understanding of the emergence of chronic viral infections and the complex molecular interactions of viruses and their hosts, and that we can thereby contribute to the development of novel antiviral therapies."

Source-Eurekalert